{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 33,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a quote from Keith Nuechterlein and specific Cohen's d effect size metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/9",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.62,
        "y": 0.38
      },
      "kind": "callout",
      "text": "Dose dependent, widespread qEEG changes observed across brain regions",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd81738f-df96-42e1-b249-c73b47ffe237",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.58,
        "x": 0.37,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Phase 2 PoM Trial Efficacy Data showing T-Scores for HVLT, Symbol Coding, and Category Fluency across 10mg, 20mg, 40mg, and 80mg doses.",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a90c0a5-1226-4323-8810-541f1cec2146",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.58,
        "x": 0.37,
        "y": 0.18
      },
      "kind": "quote",
      "text": "Symbol coding response is at a level that would correlate with better work/school performance",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe31f7b5-3889-4fcb-9bbf-47059abed58e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.37,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: CIAS = Cognitive impairment associated with schizophrenia; HVLT = Hopkins Verbal Learning Test; TID = 3x/day dosing; PoC = Proof of Concept, PoM = Proof of Mechanism. 1. Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of September 30th, 2022.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "882c082c-b438-4a2d-8b7c-570787ff2e7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.32,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "table",
      "text": "Ownership: 51.9%; Product: RL-007; Pharmacology: GABA/nicotinic modulator; Features: Pro-cognitive effects; Indications: CIAS; Status: Phase 2a/2b; IP: Patents; Highlight: 180 patients",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a81260b2-b888-442a-a247-a8dc96903745",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.13,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c613b9e-4e59-4aae-8b35-53b68c1594b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.58,
        "x": 0.37,
        "y": 0.08
      },
      "kind": "title",
      "text": "RL-007 has previously shown pro-cognitive effects in human clinical studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7f2df18-04dc-45c5-8577-95ca80739698",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 8,
      "beatId": "1052cee1-7a23-4cec-85ca-0092145b37ba",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The deck presents problem statements for various mental health indications, highlighting the unmet need for effective treatments.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 10,
      "from": 9,
      "beatId": "c03b4929-2253-4e87-9891-73e59cfb766a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck showcases traction for various programs, including RL-007, COMP360, and GRX-917, demonstrating progress and potential for growth.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}